title: Ibrutinib-induced pyoderma gangrenosum.
authors.forename: Martyna
authors.initials: M
authors.lastname: Sławińska
authors.forename: Wioletta
authors.initials: W
authors.lastname: Barańska-Rybak
authors.forename: Michał
authors.initials: M
authors.lastname: Sobjanek
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Wilkowska
authors.forename: Andrzej
authors.initials: A
authors.lastname: Mital
authors.forename: Roman
authors.initials: R
authors.lastname: Nowicki
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010880:Piperidines; D011241:Prednisone / Q000627:therapeutic use*; D017511:Pyoderma Gangrenosum / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D011720:Pyrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D016572:Cyclosporine; D000225:Adenine; D011241:Prednisone